Sarepta Therapeutics, INC Form 4 insider transactions

Michael Severino, Chief Executive Officer and a Director of Sarepta Therapeutics, Inc., reported multiple transactions in common stock on July 28, 2026.

Sarepta Therapeutics director Kathryn Boor was granted 16,875 restricted stock units as part of an equity compensation award.

Sarepta Therapeutics director Stephen Mayo was granted 16,875 restricted stock units as part of standard equity compensation.

Director Hans Wigzell was granted 16,875 restricted stock units in Sarepta Therapeutics, Inc.

Sarepta Therapeutics director M. Kathleen Behrens was granted 16,875 restricted stock units as part of an equity compensation plan.

Sarepta Therapeutics director Deirdre Connelly was granted 16,875 restricted stock units as part of an equity compensation award.

Sarepta Therapeutics Director Claude Nicaise was granted 16,875 restricted stock units as part of an equity compensation award.

Director Michael Chambers acquired 16,875 restricted stock units in Sarepta Therapeutics, Inc. as part of an equity grant.

Sarepta Therapeutics Director Richard Barry was granted 16,875 restricted stock units as part of annual equity compensation.

Sarepta Therapeutics' Chief Operating Officer, Ian Michael Estepan, reported a disposition of 1,097 shares of common stock for tax withholding purposes.

Sarepta Therapeutics' CFO, Ryan Ho-Yan Wong, reported a disposition of 256 common shares to cover tax obligations related to RSU vesting.

Sarepta Therapeutics' President of R&D and Tech Ops, Louise Rodino-Klapac, reported a disposition of 948 shares of common stock to cover tax obligations from restricted stock unit vesting.

Sarepta Therapeutics Director Stephen Mayo sold 7,239 shares of common stock to cover tax liabilities from restricted stock unit vesting.

Sarepta Therapeutics EVP and General Counsel Cristin Rothfuss had 974 shares withheld for tax obligations related to restricted stock unit vesting.

Sarepta Therapeutics' EVP and General Counsel, Cristin Rothfuss, disposed of 408 common shares to cover tax obligations related to restricted stock unit vesting.

Sarepta Therapeutics' Chief Financial Officer, Ryan Ho-Yan Wong, reported a disposition of 450 common shares to satisfy tax withholding obligations related to restricted stock unit vesting.

Sarepta Therapeutics' Chief Operating Officer, Ian Michael Estepan, reported changes in his beneficial ownership of common stock following PSU vesting and tax-related dispositions.

Sarepta Therapeutics' President of R&D and Tech Ops, Louise Rodino-Klapac, reported the vesting of performance stock units and restricted stock units, followed by tax-related share dispositions.

Sarepta Therapeutics' Chief Operating Officer, Ian Michael Estepan, exercised stock options to acquire 7,450 shares of common stock at $13.71 per share.

Sarepta Therapeutics' Chief Operating Officer, Ian Michael Estepan, earned 1,875 performance stock units based on company milestone achievement, vesting in March 2026.

Sarepta Therapeutics' President of R&D and Tech Ops, Louise Rodino-Klapac, earned 1,875 performance stock units based on company milestone achievement.

Sarepta Therapeutics Director Claude Nicaise exercised stock options and increased direct beneficial ownership of common stock.

Sarepta Therapeutics Director M. Kathleen Behrens exercised stock options and had shares withheld to cover the exercise price.

Sarepta Therapeutics director Michael Chambers exchanged $20 million in 2027 convertible notes for new 2030 notes and over $2.1 million in cash.

Sarepta Therapeutics' Chief Operating Officer, Ian Michael Estepan, sold 13,187 shares of common stock to cover tax liabilities from restricted stock unit vesting.

Sarepta Therapeutics' CFO, Ryan Ho-Yan Wong, disposed of 158 shares of common stock on December 1, 2025, to cover tax withholding obligations from RSU vesting.

Sarepta Therapeutics CEO Douglas S. Ingram received significant equity grants, increasing his beneficial ownership to 929,391 shares.

Sarepta Therapeutics' EVP and General Counsel, Cristin Rothfuss, reported a disposition of 229 common shares for tax withholding purposes related to restricted stock unit vesting.

Sarepta Therapeutics' President of R&D and Tech Ops, Louise Rodino-Klapac, disposed of 4,582 shares of common stock to cover tax obligations from RSU vesting.

Sarepta Therapeutics' President of R&D and Tech Ops, Louise Rodino-Klapac, received grants of 143,875 restricted stock units on September 3, 2025.